Gene Silencing

From Nano World Order - Wiki

Gene silencing refers to a suite of molecular techniques — and natural biological processes — that suppress or switch off the expression of specific genes, preventing the production of the proteins they encode. Where mRNA Technology and gene therapy add new protein-production instructions to cells, gene silencing removes or blocks existing ones. Together, these two directions represent a singular underlying capability: exogenous control of cellular protein expression. A cell can be made to produce something it ordinarily would not, or made to stop producing something it ordinarily does — and increasingly, both can be achieved in the same formulation.

Gene silencing technologies range from short synthetic RNA sequences to epigenetic editors that rewrite how DNA is accessed, and from approved therapeutics for rare diseases to speculative tools with potential dual-use applications in biosecurity and, according to some researchers, population-level biological management.

RNA interference mechanism showing siRNA and the RISC complex

RNA Interference (RNAi)

RNA interference is the foundational mechanism underlying most modern gene silencing approaches. It was first formally described by Andrew Fire and Craig Mello in 1998 — work that earned them the Nobel Prize in Physiology or Medicine in 2006 — though the underlying biological phenomenon had been observed in plants years earlier.

The mechanism works as follows:

  1. A short double-stranded RNA sequence (typically 21–23 nucleotides long) matching the target messenger RNA (mRNA) is introduced into the cell. These are called small interfering RNAs (siRNAs).
  2. One strand of the siRNA is loaded into the RNA-Induced Silencing Complex (RISC), a multi-protein assembly built around the Argonaute protein family.
  3. RISC uses the siRNA strand as a guide, scanning for complementary mRNA sequences in the cytoplasm.
  4. Upon finding a match, RISC cleaves and degrades the target mRNA before it can be translated into protein at the ribosome.

The result is selective suppression of a specific protein — determined entirely by the sequence of the introduced siRNA. By designing the siRNA sequence, a researcher (or, in principle, an adversarial actor) can choose which protein is eliminated.

Small Hairpin RNA (shRNA)

A limitation of siRNA is its transience: the sequences are not integrated into the genome and degrade over days to weeks. Small hairpin RNA (shRNA) addresses this by encoding the silencing sequence within a DNA construct that is integrated into the host genome — typically via a viral vector. Once integrated, the cell continuously produces the shRNA, which is then processed into functional siRNA by the enzyme Dicer. This creates a stable, heritable silencing effect, raising more significant questions about permanence and reversibility.

Antisense Oligonucleotides (ASOs)

Antisense oligonucleotides (ASOs) are short, single-stranded synthetic sequences of DNA or modified RNA that are designed to bind to a complementary target mRNA through Watson-Crick base pairing. Depending on the design:

  • The bound mRNA may be degraded by the enzyme RNase H, which recognises DNA-RNA hybrids.
  • The ASO may sterically block the ribosome from translating the mRNA into protein.
  • The ASO may alter splicing of the pre-mRNA, changing the final protein produced.

Several ASO-based therapeutics have received regulatory approval, providing proof of concept that synthetic oligonucleotides can be safely delivered systemically:

  • Nusinersen (brand name Spinraza) — approved for spinal muscular atrophy (SMA); delivered intrathecally to the spinal fluid.
  • Inotersen (Tegsedi) — approved for hereditary transthyretin amyloidosis; targets a protein that accumulates and damages nerves and heart tissue.
  • Mipomersen — targets apolipoprotein B mRNA, reducing LDL cholesterol production in the liver.

The existence of approved ASO drugs demonstrates that regulatory agencies have accepted the principle that synthetic sequences which suppress endogenous protein production are safe for therapeutic use — a precedent with broader implications.

CRISPR-Based Silencing

Beyond RNA interference, CRISPR technology has introduced a new class of gene silencing tools that operate at the level of the genome itself — without permanently cutting or editing the DNA sequence.

dCas9 (dead Cas9) is a catalytically inactivated version of the standard CRISPR-Cas9 enzyme. It retains the ability to be guided to a specific genomic locus by a guide RNA but cannot cut DNA. When fused to a transcriptional repressor domain (such as KRAB — Krüppel-associated box), dCas9 can be directed to the promoter region of any gene and physically block the transcriptional machinery from reading that gene.

This approach — sometimes called CRISPRi (CRISPR interference) — can silence gene expression by 90–99% without altering the DNA sequence itself. It falls within the domain of epigenome editing: changing how genes are expressed rather than what they encode.

Related techniques use dCas9 fused to DNA methyltransferases, which chemically mark gene promoters with methyl groups — silencing them in a potentially heritable manner. The intersection of CRISPR-based silencing with epigenetic modification represents one of the most powerful and least-reversible forms of gene control currently under development.

CRISPR-Cas9 mechanism used as basis for dCas9 silencing

MicroRNA-Based Regulation

The human body possesses its own endogenous gene silencing system in the form of microRNAs (miRNAs). These are short (approximately 22-nucleotide) non-coding RNA sequences encoded within the genome itself, which regulate protein expression in a similar fashion to siRNA — binding to target mRNAs and suppressing their translation or promoting their degradation.

The human genome encodes over 2,000 known microRNAs, and each can regulate hundreds of different mRNA targets simultaneously. MicroRNAs are therefore master regulators of cellular state, identity, and function. Disruption of normal microRNA patterns is associated with cancer, neurodegeneration, cardiovascular disease, and immune dysfunction.

Researchers have developed synthetic microRNA mimics — artificially produced sequences that replicate or supplement endogenous microRNA activity — as therapeutic tools. These are being explored for cancer treatment, liver disease, and cardiac repair.

Exosomal and Nanoparticle Delivery

A significant area of research involves delivering microRNAs (or microRNA inhibitors, called antagomirs) via exosomes — naturally occurring cell-derived vesicles that carry RNA cargo between cells — or via synthetic lipid nanoparticles. This mirrors the delivery infrastructure used in COVID-19 mRNA vaccines.

Some independent researchers have raised the question of whether mRNA vaccine formulations may affect endogenous microRNA regulation, either through direct sequence complementarity between vaccine-encoded RNA and cellular microRNA targets, or through the inflammatory and cellular stress responses triggered by lipid nanoparticle delivery. Dr. Ana Maria Mihalcea and others have called for systematic microRNA profiling in vaccinated versus unvaccinated populations. To date, peer-reviewed studies on this specific question remain limited.

Delivery Mechanisms

Gene silencing sequences — whether siRNA, ASO, or microRNA mimics — are naked RNA or DNA molecules that would be rapidly degraded in biological fluids and cannot penetrate cell membranes unaided. Effective delivery requires carriers:

Lipid Nanoparticles

Lipid Nanoparticles (LNPs) are currently the dominant delivery vehicle for siRNA and mRNA therapeutics. The first approved siRNA drug — patisiran (Onpattro, 2018), for hereditary transthyretin amyloidosis — uses LNPs to deliver siRNA to liver cells. LNPs are taken up by cells via endocytosis and release their RNA cargo into the cytoplasm. The same LNP platform underpins the BioNTech/Pfizer and Moderna COVID-19 vaccines. The existence of an approved, mass-deployed LNP-based delivery system is considered by some researchers to be infrastructure that is equally applicable to silencing payloads as to expression payloads.

GalNAc Conjugates

For liver-targeted delivery, siRNA sequences can be conjugated to N-acetylgalactosamine (GalNAc), a sugar that binds with high affinity to the ASGR1 receptor, which is expressed almost exclusively on hepatocytes (liver cells). This allows subcutaneously injected siRNA to accumulate specifically in the liver — enabling drugs like inclisiran (discussed below) to be administered as infrequent injections rather than infusions.

Viral Vectors

Viral vectors — typically adeno-associated viruses (AAV) or lentiviruses — are used to deliver shRNA constructs for stable, long-term gene silencing. These are used in laboratory settings and clinical trials involving inherited diseases. Lentiviral vectors integrate shRNA constructs into the genome of dividing cells, producing permanent silencing in the target lineage. See also Viral Vectors.

Therapeutic Applications

Gene silencing technologies are advancing rapidly through clinical development:

  • Inclisiran — a GalNAc-conjugated siRNA targeting PCSK9 in the liver, reducing LDL cholesterol synthesis. Administered twice yearly by subcutaneous injection; approved in the EU and USA.
  • Patisiran and vutrisiran — siRNA drugs for hereditary transthyretin amyloidosis, silencing the gene producing the misfolded protein that damages nerves.
  • Givosiran — siRNA for acute hepatic porphyria.
  • Fitusiran — siRNA targeting antithrombin, used in haemophilia.
  • Cancer applications — silencing oncogenes (genes that drive tumour growth) or silencing genes that confer chemotherapy resistance.
  • Neurological disease — experimental siRNA approaches to silence huntingtin (Huntington's disease) or SOD1 (ALS); delivered to the CNS via intrathecal injection or viral vector.
Lipid nanoparticle used for RNA therapeutic delivery

Concerns and Weaponisation Potential

While gene silencing has legitimate medical applications, the same technology carries dual-use implications that have attracted the attention of biosecurity researchers, ethicists, and independent investigators.

Species- and Population-Specific Targeting

Because siRNA acts by sequence complementarity, it can in principle be designed to silence a gene that is expressed in a particular way only in a specific population — for example, a genetic variant associated with a particular ethnic group. Some researchers have noted that this raises the spectre of ethnically targeted biological weapons: a siRNA payload optimised to silence a gene whose variant allele is distributed unevenly across populations. This concern intersects with broader discussions about Eugenics and the historical weaponisation of biological knowledge. The Biological Weapons Convention does not explicitly address nucleic-acid-based agents designed for selective population effects.

DARPA-Funded Environmental RNAi

DARPA's Insect Allies programme — publicly disclosed in 2016 — funded research into using insects as vectors to deliver genetically modifying organisms (including silencing constructs) to crops in the field, effectively deploying gene silencing agents in the open environment. Critics, including a group of European scientists writing in Science in 2018, warned that such systems could be repurposed as weapons capable of devastatingly affecting food crops — or, theoretically, human populations — without traceable delivery mechanisms.

RNA Pesticides and Environmental Exposure

RNA-based pesticides — products containing dsRNA or siRNA designed to silence essential genes in pest insects — are under active commercial development. BioDirect (Bayer) and similar platforms spray siRNA sequences directly onto crops. The concern raised by some researchers is that environmental siRNA could, through ingestion of plant material, enter the human gut and potentially interact with human gene expression. Studies in China (Zhang et al., 2012) suggested that plant miRNAs could be detected in human blood after eating, though replication of these findings has been inconsistent.

Connection to COVID-19 Vaccine Controversy

Several independent researchers and clinicians have raised questions about whether COVID-19 mRNA vaccine formulations may contain, or inadvertently generate, sequences with gene-silencing activity.

Dr. Ana Maria Mihalcea has raised questions regarding the complexity of self-assembling structures observed in vaccine vials and blood samples, suggesting that the biological effects of LNP-delivered RNA may extend beyond simple spike protein expression. Researcher Mik Andersen (Corona2Inspect) has published analyses suggesting that portions of the BNT162b2 mRNA sequence may have complementarity to endogenous human microRNA sequences — potentially acting as microRNA sponges or inhibitors.

Ricardo Delgado and the team at La Quinta Columna have proposed that Graphene Oxide components in vaccine formulations may function as gene expression modulators in their own right, though this remains disputed.

These claims have not been confirmed by mainstream regulatory review, but independent researchers argue that thorough microRNA and transcriptomic profiling of vaccinated individuals has not been conducted by regulatory bodies such as the FDA or EMA.

Cross-Links

Related pages on this wiki:

Retrieved from "https://nanoworldorder.com/wiki/index.php?title=Gene_Silencing&oldid=1897"